ImmunoBrain’s study write-up explores a peripheral immune-checkpoint approach in Alzheimer’s, previewing clinical biomarker-focused early-stage research.
Key Takeaways
- Clinical-stage company published peer-reviewed Phase 1b data on its lead candidate
- But the more interesting finding sits in the fluid biomarker data
- They have been following the longevity sector since 2022